Form 4: Director Receives Stock Grant

Stephen J. Galli, a Director at Atossa Therapeutics, Inc., was granted 10,000 restricted stock units on May 12, 2026.

Summary

• Stephen J. Galli, a Director of Atossa Therapeutics, Inc., received a grant of 10,000 restricted stock units (RSUs) on May 12, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs are scheduled to vest on the first anniversary of May 12, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation grant to a director rather than a significant financial transaction or strategic development.

Positives

• Director Stephen J. Galli received a stock grant, indicating potential alignment of management interests with shareholders.
• The grant of 10,000 RSUs suggests confidence in the company's future prospects by the compensation committee or board.

Future Outlook

The RSUs are set to vest on May 12, 2027, at which point Stephen J. Galli will be entitled to receive the underlying shares of common stock, subject to the terms of the grant.

Industry Context

StockSavvy.ai notes that grants of restricted stock units are a common form of executive and director compensation in the biotechnology and pharmaceutical sectors, used to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns director incentives with shareholder interests, potentially leading to decisions that enhance shareholder value.
• Employees: This transaction does not directly impact employees but reflects standard compensation practices within the company.

Next Steps

• Vesting of 10,000 RSUs on May 12, 2027.
• Potential issuance of 10,000 shares of common stock to Stephen J. Galli upon vesting.

Key Dates

Keywords

Atossa Therapeutics, ATOS, Form 4, Insider Trading, Stock Grant, Restricted Stock Units, RSU, Director Compensation, Beneficial Ownership